Compounds > hs 1793
Page last updated: 2024-11-12

hs 1793

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(6-hydroxy-2-naphthyl)-1,3-benzenediol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16215105
CHEMBL ID248499
MeSH IDM0536128

Synonyms (21)

Synonym
hs-1793
hs 1793
4-(6-hydroxy-2-naphthyl)-1,3-benzenediol
bdbm50197244
4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol ,
CHEMBL248499 ,
927885-00-5
unii-5ywk2uv4r5
5ywk2uv4r5 ,
brd-6688;brd 6688
BCP17387
AS-16807
AKOS037643535
EX-A4732
4-(6-oxidanylnaphthalen-2-yl)benzene-1,3-diol
1,3-benzenediol, 4-(6-hydroxy-2-naphthalenyl)-
4-(6-hydroxy-2-naphthalenyl)1,3-benzenediol
CMB88500
CS-0103797
HY-129156
AC-36623
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)0.03400.03403.987110.0000AID305160
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID757918Reduction of ouabain-induced mitochondrial calcium flux in Sprague-Dawley rat cardiomyocytes at 10 uM after 15 mins by Rhod 2AM staining relative to control2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage.
AID305160Inhibition of mushroom tyrosinase2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase.
AID757921Cardioprotective activity in Sprague-Dawley rat cardiomyocytes assessed as prevention of hypoxia/reoxygenation-induced collapse of state 3 respiration in presence of 100 uM ADP2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage.
AID757922Cardioprotective activity in Sprague-Dawley rat heart assessed as reduction of hypoxia/reoxygenation-induced infarct size at 10 uM treated 30 mins before reoxygenation by triphenyltetrazolium chloride staining (Rvb = 42.10 +/- 7.36%)2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage.
AID757920Cardioprotective activity in Sprague-Dawley rat cardiomyocytes assessed as reduction of hypoxia/reoxygenation-induced mitochondrial superoxide level at 10 uM after 15 mins by MitoSOX red staining relative to control2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage.
AID757919Cardioprotective activity in Sprague-Dawley rat cardiomyocytes assessed as reduction of hypoxia/reoxygenation-induced mitochondrial calcium flux at 10 uM after 15 mins by Rhod 2AM staining relative to control2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage.
AID757917Inhibition of calcium-induced cardiac mitochondria swelling in Sprague-Dawley rat at 1 uM after 10 mins2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (21.05)29.6817
2010's14 (73.68)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.89 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroquinone
[no description available]		2.4420benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
kojic acid
[no description available]		2.44204-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.1510chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		4.34180naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		3.77100resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		3.6890stilbene
6-(3-hydroxyphenyl)-2-naphthol
6-(3-hydroxyphenyl)-2-naphthol: has inhibitory effects on tyrosinase activity and melanin synthesis; structure in first source		2.0310
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.5120
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.2510
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Anoxemia
[description not available]		02.5120
Injury, Myocardial Reperfusion
[description not available]		02.0810
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.5120
Experimental Mammary Neoplasms
[description not available]		02.5820
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.1510
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.1510
Kahler Disease
[description not available]		02.1710
Local Neoplasm Recurrence
[description not available]		02.1710
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		02.1710
Angiogenesis, Pathologic
[description not available]		02.5120
Cancer of Prostate
[description not available]		02.4820
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.4820
Breast Cancer
[description not available]		02.4920
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.4920
Benign Neoplasms
[description not available]		02.4920
Invasiveness, Neoplasm
[description not available]		02.110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4920
Cancer of Colon
[description not available]		02.1510
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1510
Adenocarcinoma Of Kidney
[description not available]		02.0510
Cancer of Kidney
[description not available]		02.0510
Acute Promyelocytic Leukemia
[description not available]		02.0510
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		02.0510
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.0510
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		02.0510
Polyploid
[description not available]		02.0610
B16 Melanoma
[description not available]		02.0310